Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial.
Hansen LS, Gasbjerg LS, Brønden A, Dalsgaard NB, Bahne E, Stensen S, Hellmann PH, Rehfeld JF, Hartmann B, Wewer Albrechtsen NJ, Holst JJ, Vilsbøll T, Knop FK. Hansen LS, et al. Among authors: stensen s. Eur J Endocrinol. 2024 Aug 5;191(2):192-203. doi: 10.1093/ejendo/lvae095. Eur J Endocrinol. 2024. PMID: 39049802 Clinical Trial.
The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humans.
Krogh LSL, Henriksen K, Stensen S, Skov-Jeppesen K, Bergmann NC, Størling J, Rosenkilde MM, Hartmann B, Holst JJ, Gasbjerg LS, Knop FK. Krogh LSL, et al. Among authors: stensen s. Eur J Endocrinol. 2023 Jan 10;188(1):lvac015. doi: 10.1093/ejendo/lvac015. Eur J Endocrinol. 2023. PMID: 36651162
Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity.
Stensen S, Krogh LL, Sparre-Ulrich AH, Dela F, Hartmann B, Vilsbøll T, Holst JJ, Rosenkilde MM, Christensen MB, Gasbjerg LS, Knop FK. Stensen S, et al. Diabetes Obes Metab. 2022 Sep;24(9):1882-1887. doi: 10.1111/dom.14736. Epub 2022 Jun 20. Diabetes Obes Metab. 2022. PMID: 35491518 No abstract available.
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K; AMPLITUDE-O Trial Investigators. Gerstein HC, et al. N Engl J Med. 2021 Sep 2;385(10):896-907. doi: 10.1056/NEJMoa2108269. Epub 2021 Jun 28. N Engl J Med. 2021. PMID: 34215025 Free article. Clinical Trial.
Effects of endogenous GIP in patients with type 2 diabetes.
Stensen S, Gasbjerg LS, Krogh LL, Skov-Jeppesen K, Sparre-Ulrich AH, Jensen MH, Dela F, Hartmann B, Vilsbøll T, Holst JJ, Rosenkilde MM, Christensen MB, Knop FK. Stensen S, et al. Eur J Endocrinol. 2021 May 21;185(1):33-45. doi: 10.1530/EJE-21-0135. Eur J Endocrinol. 2021. PMID: 33886495
The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes.
Dalsgaard NB, Gasbjerg LS, Hansen LS, Hansen NL, Stensen S, Hartmann B, Rehfeld JF, Holst JJ, Vilsbøll T, Knop FK. Dalsgaard NB, et al. Among authors: stensen s. Eur J Endocrinol. 2021 Mar;184(3):383-394. doi: 10.1530/EJE-20-1121. Eur J Endocrinol. 2021. PMID: 33449919 Clinical Trial.
18 results